Is AIM ImmunoTech Inc. (AIM) a Buy, Sell, or Hold?
AMEX : AIM
AIM ImmunoTech Inc.
$0.2854 USD
$0.01 (5.39%)
- Volume
- 953.17K
- Average Volume
- 27.95M
- Market Capitalization
- $971.37K
- P/E Ratio
- -0.31
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.89
- Year Low
- $0.21
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.11
Company Overview
AMEX
Thomas K. Equels
Biotechnology
Healthcare
AIM
19
US
USD
Liquidity Metrics
0.04
2.11
2.11
2.00
0.00
Sales & Valuation
$88000
10.22
0.63
-0.14
-0.42
Profitability
-$8.62
-$13.96M
-15021.05%
-15021.05%
952.76%
-112.09%
P/E Metrics
-0.31
0.00
0.00
Analyst Price Target & Rating
1/5
3 Analysts
%
Financial Health Scores
-76.99
3/9
$69000.0
$8.58M
$6.46M
-$12.28M
Key Metrics (TTM)
-$320.32K
-3.41
0.03
1.01
261.84%
-152.10%
-1126.64%
-1266.38%
-2025 days
Company Executives
| Name | Title |
|---|---|
| Peter W. Rodino | Chief Operating Officer, Executive Director of Governmental Relations, General Counsel & Secretary |
| Robert Dickey | Chief Financial Officer |
| Ann Marie E. Coverly | Director of Administration & Human Resources and Deputy Investor Relations Coordinator |
| Thomas K. Equels | Executive Vice Chairman, Chief Executive Officer & President |
| Christopher Nicodemus FACP | Member of Scientific Advisory Board & Consulting Science Officer |
Poll Results
No votes yet today — be the first to share your view!
About AIM ImmunoTech Inc. (AMEX:AIM) Stock
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, ... HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Major boon predicted for Jersey Oil & Gas as bullish broker repeats Buy rating
2026-08-06 17:54:46
Cavendish sees almost fivefold upside in Jersey Oil and Gas PLC (AIM:JOG, OTC:JYOGF) after regulators extended the Verbier licence, giving the partners more time to advance an integrated Greater Buchan Area development. The broker has repeated a Buy recommendation and 537p price target, representing 388% upside from the AIM-listed company's 110p share price.
AIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection Point
2026-08-03 08:33:00
Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027
Admission to Trading on the Main Market and AIM Cancellation
2026-07-31 02:00:00
Reykjavík, July 31, 2026 (GLOBE NEWSWIRE) -- THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE COMMON SHARES IN AMAROQ LTD. IN ANY JURISDICTION.
Cavendish sees 18-fold upside at 88 Energy on Alaska prospect scale
2026-07-22 07:59:49
Cavendish has reiterated its buy rating and 19.8p target price on 88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ), implying significant untapped upside from the current 1.02p share price. The AIM-listed oil and gas explorer's South Prudhoe acreage on Alaska's North Slope now holds 768.9 million barrels of gross prospective resources, of which 640.7 million barrels are net to the company.
Seeing Machines wins European carmaker deal as EU driver monitoring rules come into force
2026-07-22 02:30:06
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF, FRA:M2Z), the AIM-listed computer vision company, has secured a new driver and occupant monitoring contract with a European carmaker as fresh European Union safety rules take effect. The award, won through an existing Tier 1 supplier, is expected to generate around $5 million in lifetime revenue.
CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held
2026-07-15 02:58:42
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed cancer diagnostics company, said its commercially weighted pipeline had built to £3.5 million, supported by rising engagement from pharmaceutical and diagnostic partners. It reiterated its forecast for revenue of at least £2.1 million for the 2026 financial year, growth of at least 50% on the prior year.
2026-07-07 09:03:00
CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer
2026-07-07 09:03:00
Access it here OCALA, Fla. , July 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the release of its latest CEO Corner segment, featuring Chief Executive Officer Thomas Equels discussing the Company's continued momentum in pancreatic cancer and the significant clinical, strategic and operational milestones positioning Ampligen for its next stage of development.
Frequently Asked Questions
-
What is the current AIM ImmunoTech Inc. (AIM) stock price?
-
AIM ImmunoTech Inc.(AMEX:AIM) stock price is $0.2854 in the last trading session. During the trading session, AIM stock reached the peak price of $2.8904 while $0.21 was the lowest point it dropped to. The percentage change in AIM stock occurred in the recent session was 5.39% while the dollar amount for the price change in AIM stock was $0.01.
-
AIM's industry and sector of operation?
-
The AMEX listed AIM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AIM?
-
Peter W. Rodino | Chief Operating Officer, Executive Director of Governmental Relations, General Counsel & Secretary
Robert Dickey | Chief Financial Officer
Ann Marie E. Coverly | Director of Administration & Human Resources and Deputy Investor Relations Coordinator
Thomas K. Equels | Executive Vice Chairman, Chief Executive Officer & President
Christopher Nicodemus FACP | Member of Scientific Advisory Board & Consulting Science Officer -
How many employees does AIM have?
-
Number of AIM employees currently stands at 19. AIM operates from 2117 SW Highway 484, Ocala, FL 34473, US.
-
Link for AIM official website?
-
Official Website of AIM is: https://aimimmuno.com
-
How do I contact AIM?
-
AIM could be contacted at phone #352 448 7797 and can also be accessed through its website. AIM operates from 2117 SW Highway 484, Ocala, FL 34473, US.
-
How many shares of AIM are traded daily?
-
The average number of AIM shares traded daily for last 3 months was 27.95M.
-
What is the market cap of AIM currently?
-
The market value of AIM currently stands at $971.37K with its latest stock price at $0.2854